26 Dec, EOD - Indian

SENSEX 78472.48 (0.00)

Nifty 50 23750.2 (0.10)

Nifty Bank 51170.7 (-0.12)

Nifty IT 43664.25 (-0.01)

Nifty Midcap 100 57125.7 (0.12)

Nifty Next 50 69165.85 (0.45)

Nifty Pharma 22712.55 (0.68)

Nifty Smallcap 100 18728.65 (-0.02)

26 Dec, EOD - Global

NIKKEI 225 39568.06 (1.12)

HANG SENG 20098.29 (1.08)

S&P 6047.79 (0.05)


Hot Pursuit News

You are Here : Home > News > Hot Pursuit News >

(04 Oct 2024, 11:09)

Aarti Drugs gains after arm receives UK MHRA GMP Compliance Certificate

Aarti Drugs rose 2.57% to Rs 526.85 after the Medicines and Healthcare Products Regulatory Agency (UK MHRA) has granted a Certificate of GMP Compliance of a Manufacturer for its arm, Pinnacle Life Science’s manufacturing facility in Himachal Pradesh.


The company said that there are no financial or material impacts as of now. With the GMP compliance, Pinnacle is positioned to export its formulations to the UK market.

The firm stated that there have been no violations or alleged contraventions regarding its operations.

Aarti Drugs is primarily involved in manufacturing and marketing of Active Pharmaceutical Ingredients (API), Pharma Intermediates and Specialty Chemicals.

The company’s consolidated net profit declined 30.5% to Rs 33.24 crore on 16% slide in net sales to Rs 555.34 crore in Q1 FY25 over Q1 FY24.

More News
More Company News View Company Information